Pharming Launches Joenja in Japan for Adult, Pediatric APDS Patients

MT Newswires Live

Aug 13

Pharming (PHAR) launched Joenja in Japan for adult and pediatric patients aged 4 and older with activated PI3K delta syndrome, or APDS, following its inclusion on Japan's National Health Insurance drug price list, the company said Thursday.

The launch marks the first commercial availability of Joenja worldwide for children aged 4 to 11, the company said.

Japan's Ministry of Health, Labour and Welfare approved the treatment in March as the first treatment specifically for APDS, it added.

Joenja, or leniolisib, is an oral PI3K-delta inhibitor developed for APDS.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2659347521"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659347521\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659347521?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 16:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659347521","market":"nz","top_or_hot":-1,"title":"Pharming Launches Joenja in Japan for Adult, Pediatric APDS Patients","media":"MT Newswires Live","content":"<html><body><p> Pharming (PHAR) launched Joenja in Japan for adult and pediatric patients aged 4 and older with activated PI3K delta syndrome, or APDS, following its inclusion on Japan's National Health Insurance drug price list, the company said Thursday.</p><p>The launch marks the first commercial availability of Joenja worldwide for children aged 4 to 11, the company said.</p><p>Japan's Ministry of Health, Labour and Welfare approved the treatment in March as the first treatment specifically for APDS, it added.</p><p>Joenja, or leniolisib, is an oral PI3K-delta inhibitor developed for APDS.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharming Launches Joenja in Japan for Adult, Pediatric APDS Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharming Launches Joenja in Japan for Adult, Pediatric APDS Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-13 16:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Pharming (PHAR) launched Joenja in Japan for adult and pediatric patients aged 4 and older with activated PI3K delta syndrome, or APDS, following its inclusion on Japan's National Health Insurance drug price list, the company said Thursday.</p><p>The launch marks the first commercial availability of Joenja worldwide for children aged 4 to 11, the company said.</p><p>Japan's Ministry of Health, Labour and Welfare approved the treatment in March as the first treatment specifically for APDS, it added.</p><p>Joenja, or leniolisib, is an oral PI3K-delta inhibitor developed for APDS.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2659347521","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659347521","pubTimestamp":1786608378,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pharming  launched Joenja in Japan for adult and pediatric patients aged 4 and older with activated PI3K delta syndrome, or APDS, following its inclusion on Japan's National Health Insurance drug price list, the company said Thursday.The launch marks the first commercial availability of Joenja worldwide for children aged 4 to 11, the company said.Japan's Ministry of Health, Labour and Welfare approved the treatment in March as the first treatment specifically for APDS, it added.Joenja, or leniolisib, is an oral PI3K-delta inhibitor developed for APDS.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PHAR":"Pharming Group N.V."},"translate_title":"Pharming 在日本为成人和儿童 APDS 患者推出 Joenja","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAR":1},"content_text":"Pharming (PHAR) launched Joenja in Japan for adult and pediatric patients aged 4 and older with activated PI3K delta syndrome, or APDS, following its inclusion on Japan's National Health Insurance drug price list, the company said Thursday.The launch marks the first commercial availability of Joenja worldwide for children aged 4 to 11, the company said.Japan's Ministry of Health, Labour and Welfare approved the treatment in March as the first treatment specifically for APDS, it added.Joenja, or leniolisib, is an oral PI3K-delta inhibitor developed for APDS.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}